Oncology & Cancer

Prophylaxis with apixaban feasible for cancer patients

(HealthDay) -- Primary venous thromboembolism prophylaxis with apixaban, an oral direct Factor Xa inhibitor, in ambulatory cancer patients undergoing first- or second-line chemotherapy for advanced or metastatic cancer, is ...

Cardiology

Patient education ups VTE prophylaxis in hospital setting

(HealthDay)—A patient-centered education bundle intervention can reduce nonadministration of venous thromboembolism (VTE) prophylaxis, according to a study published online Nov. 16 in JAMA Network Open.

Oncology & Cancer

Guidelines for VTE prophylaxis, treatment in cancer unchanged

(HealthDay)—The 2014 recommendations for the prophylaxis and treatment of venous thromboembolism (VTE) in patients with cancer are unchanged from 2013, according to an article published online Jan. 20 in the Journal of ...

Obstetrics & gynaecology

Study adds to evidence on clot risks of non-oral contraceptives

A study published on BMJ website today adds to the evidence that certain non-oral hormonal contraceptives (e.g. skin patches, implants and vaginal rings) carry a higher risk of serious blood clots (known as venous thromboembolism) ...

page 8 from 24